Wolfe Research Initiates Coverage on Alkermes (NASDAQ:ALKS)

Equities researchers at Wolfe Research began coverage on shares of Alkermes (NASDAQ:ALKS) in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The brokerage set an “outperform” rating and a $45.00 price target on the stock. Wolfe Research’s target price points to a potential upside of 34.77% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on ALKS. Wells Fargo & Company decreased their price target on shares of Alkermes from $42.00 to $37.00 and set an “overweight” rating for the company in a report on Thursday, November 13th. Needham & Company LLC increased their price target on shares of Alkermes from $43.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Alkermes from $55.00 to $45.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Jefferies Financial Group set a $56.00 target price on Alkermes and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Finally, Wall Street Zen cut Alkermes from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 9th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Alkermes has a consensus rating of “Moderate Buy” and a consensus target price of $44.00.

Alkermes Trading Up 3.7%

Alkermes stock opened at $33.39 on Monday. Alkermes has a 1-year low of $25.17 and a 1-year high of $36.32. The firm’s fifty day simple moving average is $31.38 and its 200-day simple moving average is $30.17. The company has a market capitalization of $5.51 billion, a P/E ratio of 16.53 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). Alkermes had a return on equity of 21.81% and a net margin of 22.27%.The business had revenue of $384.55 million during the quarter, compared to the consensus estimate of $380.44 million. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. On average, equities research analysts predict that Alkermes will post 1.31 earnings per share for the current year.

Insider Activity at Alkermes

In other Alkermes news, Director Shane Cooke sold 61,200 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $34.57, for a total transaction of $2,115,684.00. Following the completion of the transaction, the director directly owned 103,744 shares in the company, valued at $3,586,430.08. This represents a 37.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Craig C. Hopkinson sold 9,000 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $33.93, for a total transaction of $305,370.00. Following the completion of the sale, the executive vice president owned 57,740 shares in the company, valued at $1,959,118.20. This represents a 13.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 148,148 shares of company stock valued at $5,028,378 in the last 90 days. 4.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Alkermes

Hedge funds have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. bought a new position in Alkermes during the 4th quarter valued at about $59,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Alkermes during the fourth quarter worth approximately $256,000. Summit Global Investments increased its holdings in shares of Alkermes by 48.8% during the fourth quarter. Summit Global Investments now owns 29,662 shares of the company’s stock worth $830,000 after buying an additional 9,724 shares in the last quarter. Vident Advisory LLC raised its stake in shares of Alkermes by 1.1% in the fourth quarter. Vident Advisory LLC now owns 82,294 shares of the company’s stock valued at $2,303,000 after acquiring an additional 864 shares during the last quarter. Finally, Empowered Funds LLC acquired a new position in shares of Alkermes in the 4th quarter worth approximately $1,712,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

Alkermes News Roundup

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “outperform” rating, giving the stock fresh buy-side attention that can support upward momentum. Wolfe Research initiation
• Positive Sentiment: Revenue slightly exceeded expectations: $384.6M vs. consensus $380.4M, and the company reported healthy profitability (net margin ~22.3%, ROE ~21.8%), which supports valuation metrics. Q4 press release
• Neutral Sentiment: Management provided financial expectations for 2026 and hosted an earnings webcast; guidance details (and how conservative/aggressive they are) will be closely watched in the call. Earnings release and guidance
• Neutral Sentiment: CEO succession announced: long-time CEO Richard Pops will retire July 31, 2026; COO Blair Jackson will become CEO Aug. 1 and join the board, with Pops remaining chairman — an orderly transition but one investors will monitor for strategic continuity. CEO succession plan
• Neutral Sentiment: Alkermes highlighted recent corporate events including the close of the Avadel acquisition and upcoming investor presentations (TD Cowen conference) — these can influence sentiment as more detail on integration and synergies emerges. Avadel acquisition context Conference presentation
• Negative Sentiment: Earnings per share missed consensus materially: $0.29 vs. $0.43 expected (a $0.14 shortfall), a key driver of near-term downside risk until management addresses drivers of the miss. Q4 press release

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.